Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma Source: Eur Respir J, 58 (6) 2100413; 10.1183/13993003.00413-2021 Year: 2021
Differences in clinical and inflammatory characteristics between steroid-withdrawal-induced and spontaneous exacerbations in patients with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 199s Year: 2002
The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma Source: International Congress 2017 – Bronchial asthma management Year: 2017
Real-world treatment patterns of newly diagnosed patients with asthma and/or COPD Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma Source: Eur Respir J, 52 (4) 1800936; 10.1183/13993003.00936-2018 Year: 2018
The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Influence of statin therapy on clinical symptoms, severity and prognosis in patients with community acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008
Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017
Associations between clinical, laboratory and therapeutical parameters on admission and adverse outcomes in patients hospitalized for COPD exacerbations Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010
Effects of exacerbation risk on symptoms and clinical characteristics in patients with bronchiectasis Source: Annual Congress 2012 - Assessment of physical activity, exercise, muscle function and clinical characteristics as outcomes in physiotherapy and rehabilitation Year: 2012
Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Long-term efficacy of 1 year anti-inflammatory treatment in paediatric patients with mild persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004
Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Spanish consensus on the characteristics of severe asthmatic patients under biological treatment suitable for at home administration Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
A clinical and outcomes assessment of the management of acute episodes of chronic bronchitis (AECB) : the MOSAIC study - baseline characteristics of screened patients Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002
Clinical characteristics and burden of illness in a cohort of severe asthma patients Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life Year: 2016
Clinical characteristics and outcomes in hospitalized COVID-19 patients with COPD Source: Virtual Congress 2021 – COVID-19 and obstructive diseases: risk factors, management and long-term effects Year: 2021
Study of clinical presentation and predictors of adverse outcome in patients admitted for acute exacerbation of COPD. Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019